Blog

Blog

How High-Throughput Antibody Production Removes Discovery Bottlenecks

How High-Throughput Antibody Production Removes Discovery Bottlenecks

Artificial intelligence (AI) is transforming antibody discovery by enabling researchers to design and optimize thousands of antibody sequences in a fraction of the time required by traditional approaches. However, while computational design has become increasingly efficient, experimental validation has struggled to keep pace.

Nov 11, 2026
Read time: 5 mins
Three Routes from Antibody Sequence to Experimental Data

Three Routes from Antibody Sequence to Experimental Data

AI-driven antibody discovery has made it possible to generate thousands of candidate sequences in a single design cycle. However, computational predictions alone cannot confirm whether an antibody will express efficiently, bind its intended target, or demonstrate properties suitable for further development. Experimental validation remains essential.

Nov 06, 2026
Read time: 3 mins
How Antibody Structure Prediction Supports AI Antibody Design

How Antibody Structure Prediction Supports AI Antibody Design

Learn how predicted antibody structures help screen AI-designed candidates, assess CDR-H3 limits, and why wet lab validation remains essential.

Nov 02, 2026
Read time: 10 mins
How to Select the Right RushDATA™ Workflow

How to Select the Right RushDATA™ Workflow

Compare RushDATA Basic, Standard and Premium: BLI affinity, SPR kinetics, DSF, PSR-BVP and AC-SINS for AI-designed antibodies. Data in 2-3 days.

Oct 27, 2026
Read time: 3 mins
World ADC 2026 – San Diego: Highlights and Event Recap

World ADC 2026 – San Diego: Highlights and Event Recap

The 17th Annual World ADC San Diego Summit highlighted novel payload mechanisms, antibody engineering, bispecific and dual-payload ADCs, and clinical translation. Emerging strategies to improve therapeutic efficacy, overcome treatment resistance, and expand therapeutic windows were also discussed.

Oct 21, 2026
Read time: 10 mins
Therapeutically Relevant Antibody Data Starts with the Right Expression System

Therapeutically Relevant Antibody Data Starts with the Right Expression System

Recombinant antibody production involves introducing the genetic sequence encoding an antibody into a suitable expression host. The host's cellular machinery then produces the protein, which can be collected and purified for downstream analysis.

Oct 19, 2026
Read time: 6 mins
How is AI Used in Antibody Discovery?

How is AI Used in Antibody Discovery?

Antibody discovery has traditionally relied on screening large libraries of molecules to identify candidates that recognize a specific target. Although established techniques such as hybridoma technology and phage display have been successful, identifying and optimizing promising antibodies can require extensive experimental work.

Oct 16, 2026
Read time: 7 mins
Roundup of Antibody Biotech Deals in September 2026

Roundup of Antibody Biotech Deals in September 2026

Explore September 2026 antibody biotech deals, including major licensing agreements, ADC collaborations, bispecific antibodies, AI drug discovery, and financing rounds.

Oct 12, 2026
Read time: 8 mins
From Assay Results to Model-Ready Antibody Datasets

From Assay Results to Model-Ready Antibody Datasets

As AI models become more involved in antibody discovery and design, the need for reliable experimental data is growing. Turning predicted sequences into structured, comparable assay results is an important step towards connecting computational predictions with laboratory evidence.Antibody design is

Oct 05, 2026
Read time: 8 mins
Antibodies After Hours: Antibodies Meet AI – Boston 2026

Antibodies After Hours: Antibodies Meet AI – Boston 2026

Recap of Antibodies After Hours Boston 2026: IPI's DELPHI developability prediction, CDR H3 polyreactivity insights, and Biointron's RushDATA™ wet-lab platform.

Oct 02, 2026
Read time: 4 mins
World Bispecific Summit – Boston: Highlights and Event Recap

World Bispecific Summit – Boston: Highlights and Event Recap

Key trends from the 17th World Bispecific Summit 2026 in Boston: AI-guided design, CD2/CD28 T-cell engagers, conditional antibodies, multispecific ADCs.

Sep 21, 2026
Read time: 10 mins
Antibodies After Hours: From Algorithms to Antibodies – South San Francisco

Antibodies After Hours: From Algorithms to Antibodies – South San Francisco

Biointron’s Antibodies After Hours: From Algorithms to Antibodies was held at The Hangar in South San Francisco, on Friday, September 4, 2026. “Antibodies After Hours” is a networking reception series from Biointron held in biotech hubs across the United States, with events previously hosted in S

Sep 16, 2026
Read time: 3 mins

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.